{"entity":{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","aka":[],"tldr":"A phase 3 trial of Belantamab mafodotin, Daratumumab, Bortezomib in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06868654 by GlaxoSmithKline, with 72 participants enrolled, started 2021-07-28 and due to reach its primary completion in 2024-04-03. Interventions recorded: Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06868654","url":"https://clinicaltrials.gov/study/NCT06868654"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc","antiemetic-therapy","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["belantamab-mafodotin","daratumumab","bortezomib","dexamethasone"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06868654","phase":"3","setting":"DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","started":"2021-07-28","startedType":"actual","yearReported":2025,"enrolled":72,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)","n":32,"note":"The median and upper limit 95% Confidence Interval were not estimable due to the length of follow-up in assessing the number of events.; Figures from the ClinicalTrials.gov results section (first posted 2025-04-23), not from a publication"},{"name":"Daratumumab + Bor + Dex","n":40,"value":8.4,"note":"95% CI 4.9 to 21.5"}],"hr":0.24,"ci":[0.11,0.56],"source":"https://clinicaltrials.gov/study/NCT06868654?tab=results"}]},"route":"/trials/nct06868654/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}